Literature DB >> 15247455

Support for the RV144 HIV vaccine trial.

Robert Belshe, Genoveffa Franchini, Marc P Girard, Frances Gotch, Pontiano Kaleebu, Marta L Marthas, Michael B McChesney, Rose McCullough, Fred Mhalu, Dominique Salmon-Ceron, Rafick-Pierre Sekaly, Koen van Rompay, Bernard Verrier, Britta Wahren, Mercedes Weissenbacher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15247455     DOI： 10.1126/science.305.5681.177b

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  9 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

2.  Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Authors:  Sharon E Frey; Laurence Peiperl; M Juliana McElrath; Spyros Kalams; Paul A Goepfert; Michael C Keefer; Lindsey R Baden; Michelle A Lally; Kenneth Mayer; William A Blattner; Clayton D Harro; Scott M Hammer; Geoffrey J Gorse; John Hural; Georgia D Tomaras; Yves Levy; Peter Gilbert; Allan deCamp; Nina D Russell; Marnie Elizaga; Mary Allen; Lawrence Corey
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

3.  Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.

Authors:  Ranajit Pal; David Venzon; Sampa Santra; Vaniambadi S Kalyanaraman; David C Montefiori; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Janos Nacsa; Yvette Edghill-Smith; Marcin Moniuszko; Zdenek Hel; Igor M Belyakov; Jay A Berzofsky; Robyn Washington Parks; Phillip D Markham; Norman L Letvin; Jim Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown.

Authors:  Peter A Newman; Carmen Logie; Llana James; Tamicka Charles; John Maxwell; Khaled Salam; Michael Woodford
Journal:  Am J Public Health       Date:  2011-07-21       Impact factor: 9.308

Review 5.  Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

Authors:  Monica Vaccari; Poonam Poonam; Genoveffa Franchini
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

6.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

7.  HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

Authors:  Mangala Rao; Kristina K Peachman; Jiae Kim; Guofen Gao; Carl R Alving; Nelson L Michael; Venigalla B Rao
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

8.  Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.

Authors:  Poonam Pegu; Monica Vaccari; Shari Gordon; Brandon F Keele; Melvin Doster; Yongjun Guan; Guido Ferrari; Ranajit Pal; Maria Grazia Ferrari; Stephen Whitney; Lauren Hudacik; Erik Billings; Mangala Rao; David Montefiori; Georgia Tomaras; S Munir Alam; Claudio Fenizia; Jeffrey D Lifson; Donald Stablein; Jim Tartaglia; Nelson Michael; Jerome Kim; David Venzon; Genoveffa Franchini
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 9.  Modulation of HIV-1 immunity by adjuvants.

Authors:  M Anthony Moody
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.